Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NivoMes Study of nivolumab monotherapy in progressive malignant pleural mesothelioma
NL-OMON41970Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in pleural mesothelioma, sponsored by Netherlands Cancer Institute. Primary endpoint: Disease control rate at 12 weeks. Started Jul 2015; status: active, not recruiting.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON41970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41970.